Introduction
Prognosis remains one of the major challenges in multiple sclerosis (MS), for the patient as well as for the physician, despite considerable efforts concentrating for decades on the description of prognosis and its potentially influencing factors [1 ] . Modern survival techniques allow us to consider not only patients who have reached the endpoints under study (death or, most frequently, irreversible disability), but also those who remain alive or not disabled at the date of their last visit, for the time they have been followed. Improvements in the quality and representativity of epidemiological studies have also led to a better knowledge of the prognosis, with prospective, population-based, natural history studies, and longitudinal and long-term follow-up [2, 3] .
The general evolution of MS is well described among groups of patients and results are consistent among studies worldwide [1 ] , despite some recent reports of series with a better global prognosis [4,5,6 ,7] . Thus, the median times to reach irreversible DSS 4 (limited walking ability but without aid or rest for more than 500 m), DSS 6 (ability to walk with unilateral support no more than 100 m without rest) and DSS 7 (ability to walk no more than 10 m without rest while leaning against a wall or holding onto furniture for support) are about 8, 20 and 30 years respectively. By contrast, the individual prognosis is still hazardous, and neither clinical data, conventional magnetic resonance imaging (MRI), nor biological markers are actually helpful for a specific case.
Relapses and progression as prognostic factors
Among the various prognostic factors, characteristics of relapses in the first years of the disease and the occurrence of a progressive phase seemed to be the most reliable. On one hand, it is well established that the evolution to an irreversible disability, whatever the score, takes longer in patients with an exacerbating-remitting onset, compared to those with a progressive one. The transition from a relapsing-remitting phase to a secondary progression is also associated with a worse evolution. On the other hand, factors related to relapses, as a monosymptomatic onset, with an optic neuritis, a complete recovery, a long time interval between the first and the second relapse, and a lower number of relapses within the first years, have consistently been associated with a better prognosis [1 ,8] .
However, these concepts have been debated in recent papers published at the same time by different teams. They questioned, in term of prognosis, the interplay between relapses and progression of disability. Kremenchutzky et al. [9 ] explored once again the London, Ontario, MS database to examine the relationship between relapses, onset of the progressive phase and long-term disability accumulation. In two sets of patients they distinguished 219 patients with primary progressive MS (PP-MS), 140 with a single attack, followed at some time by progression (SAP-MS) and 817 with secondary progressive MS (SP-MS). These categories were chosen as they represented extremes in term of interaction between relapses and progression: from no relapse, to an isolated one, to many before the onset of progression. They showed that age at disease onset was different between groups (38.6, 33.3 and 29.8 years in PP-MS, SAP-MS and SP-MS), but conversely, that age at which progression begins was similar whatever the number of previous relapses (38.6, 40.9 and 39.2 years respectively). Furthermore, times from MS onset to disability landmarks were significantly longer in SAP-MS and SP-MS than in PP-MS patients, but times from onset of the progressive phase to disability landmarks were similar in the three groups (Fig. 1) . They concluded that the progressive phase in MS could be an age-dependent, degenerative process, independent of previous relapses, whatever their number. Once progression has begun, its rate is largely independent of the past clinical history [10, 11, 12] .
Interestingly, Confavreux and Vukusic [13 ] reached similar conclusions from another perspective. Considering that all previous studies focused only on assessment of the times to reach disability milestones and not ages at which patients reach these landmarks, and that onset of the relapsing-remitting and the progressive phases have repeatedly been demonstrated to be age-related (Fig. 2) [14 ], independently of the overall course of the disease, they decided to compare ages at which patients reach disability milestones according to their clinical course at the time of the study. They therefore analysed the 1844 patients from the Lyon MS database, an historical cohort set up in 1976. Patients with an exacerbating-remitting MS onset numbered 1562, whereas patients with a course that was progressive from onset were 282. Among the patients with an exacerbating-remitting initial course, 496 evolved later to secondary progression. Median ages at time to assignment of irreversible disability were 44.3 years for a score of DSS 4, 54.7 years for DSS 6 and 63.1 years for DSS 7. The initial course of the disease, whether exacerbating-remitting or progressive, had a statistically significant influence on ages at assignment of DSS 4 and DSS 6, but the differences were only marginal for the medians, with an overlap in the 95% confidence intervals. There was no difference with respect to assignment of DSS 7. Here is the place for some methodological considerations. When reaching disability landmarks, patients progressive from onset were younger than those with an exacerbating-remitting onset, but older than those with a secondary progressive course. The latter likely represent a select group of more rapidly worsening patients within the subgroup of exacerbating-remitting onset. Furthermore, the higher proportion of censored patients, not having experienced the endpoints -that is, irreversible disability -among patients with an exacerbating-remitting onset, could also contribute to the observed difference by overestimating the medians, compared to patients who were progressive from onset (Fig. 3) . Therefore, the originality of this study is that it is the first to show that the initial course of the disease does not substantially influence age at disability milestones.
That said, another clinical factor is strongly and consistently associated with the time course of disability: age at MS onset. It is accepted that a younger age at onset is related to a slower disease progression and therefore a Adapted from [9 ] .
better prognosis. In the Lyon series, an earlier age at MS onset and a male gender, but not the initial symptoms, were associated with an earlier age at disability milestones, but not of the initial symptoms [13 ] . Tremlett et al. [6 ] have also given further evidence of the importance of current age. In 2837 patients followed at the University of British Columbia's MS clinic, they estimated the median time to an EDSS 6 to be 27.9 years, which is surprisingly longer than previous estimates in other series. The median age at which patients reached this endpoint was 59 years. There was no difference in ages at EDSS 6 between males and females, or according to initial symptoms. Patients with an exacerbatingremitting onset were significantly older when reaching EDSS 6 than those with a primary progressive course, but the difference was only 4 years. By contrast, a younger age at disease onset was strongly correlated with a younger age when reaching EDSS 6, confirming that even if it takes longer for younger patients to accumulate irreversible disability, they are disabled at a younger age and have to support longer the burden of the disease (Fig. 4) . A younger age at MS onset should therefore no longer be considered as a good prognostic factor.
The clinical and epidemiological dissociation between relapses and disability accumulation in the long term is not contradictory with a short-term influence of relapses on MS course. It has been shown many times for example that the higher the number of relapses in the first years of the disease, the shorter the time from disease onset to assignment of irreversible disability scores [15] . However, this relationship seems to exist only before a detectable disability threshold has been reached. The same is true for other classically described early clinical Natural history of multiple sclerosis Vukusic and Confavreux 271 Adapted from [13 ] . Adapted from [6 ] . predictors that were no longer associated with long-term outcome as estimated from DSS 4 or DSS 6 onwards [12, 16] . It also has been clearly demonstrated that relapses do have an effect on the measure of short-term disability, which might be considered as confirmed in clinical trials if persisting over 3 or 6 months, but can surely not be considered irreversible as defined in natural history studies [17] [18] [19] . This point might be crucial, as strong assumptions have been made concerning correlations between relapse frequency and disability outcomes, and they have been influencial in determining clinical trial design and interpretation. Thus, the demonstration of a short-term effect (over a 2-or 3-year period) of immunoactive treatments on reducing the relapse rate and sometimes even disability outcomes has led to the potential of predicting a change in the long-term outcome of treated patients [20, 21] . These recent results give new arguments against these hypotheses.
The currently acknowledged classification [22] Patients with a relapsing onset, be it RR-MS or SP-MS, shared similar ages at onset (28.5 and 29.5 years), initial symptoms, degree of recovery after the first relapse, and time between the first and the second episode. However, it has to be emphasized that disease duration was twice as long in SP-MS than in RR-MS. Similarly, patients with a progressive onset, with or without superimposed relapses, were comparable in their demographic and clinical characteristics. As for the onset of progression, median ages were similar in SP-MS and patients who were progressive from onset (39.1 and 40.1 years). The proportion of patients with superimposed relapses was about 40% in both subgroups. When comparing patients with an exacerbating-remitting course with those with a progressive onset, the study showed that they were essentially similar with respect to time course of disability accumulation from assignment to a given disability score, and with respect to the age at assignment of disability landmarks.
These observations suggest that the clinical phenotype and course of MS are mostly age-dependent, and lead the authors to speculate on a unifying concept of the disease, in which primary and secondary progression might be regarded as essentially similar. From a clinical and statistical position, MS might therefore be considered as one disease with different clinical phenotypes, rather than an entity encompassing several distinct diseases. RR-MS can be seen as MS in which insufficient time has elapsed for conversion to secondary progression to occur, SP-MS as RR-MS that has had time to grow older, and PP-MS as MS amputated from its usually preceding relapsing-remitting phase [1 ,14 ,20,23,24] . Therefore, the classification of MS course could be simplified as follows: onset is either exacerbating-remitting or progressive; the relapsing-remitting phase may be followed or not by a progressive phase; the progressive phase may be preceded or not by an exacerbating-remitting phase. Only three types of clinical course would remain: relapsing-remitting, secondary progressive and primary progressive, and the progressive phase may be superimposed with relapses or not [1 ,14 ,25] .
All of these data are of course applicable only at the population level. It is a challenge now to develop individually predictive tools. Bergamaschi et al. [26 ] very recently proposed an individual and simple clinical score that could be useful to detect patients likely to have a long-term bad prognosis. However, this score has to be validated on another set of patients to evaluate its predictive potential before it can be used in daily practice.
Clinically isolated syndromes
Prognosis can be considered from another point of view. In patients presenting for the first time with neurological symptoms suggesting an inflammatory demyelinating disease of the central nervous system, the crucial question is more likely to be diagnostic (do I have MS and when will I be sure of that?) than prognostic (will I become disabled and when?) [27] . Natural history studies can in part answer this question, but patients included in such studies might not be the same as those asking the question. It is for example classical to exclude patients in whom MS diagnosis is uncertain. Furthermore, these studies are interesting because they have a long follow-up duration, but conversely, this is often a reason why they do not have MRI data at baseline. It would today be difficult not to take account of MRI data. Studies of patients presenting with a clinically isolated syndrome (CIS) may therefore help. Some answers arose from immunoactive drugs trials after the first clinical episode [28] [29] [30] [31] [32] [33] , but they are unlikely to be representative of patients seen in daily practice, as their inclusion criteria were rather restrictive in terms of the severity of symptoms, time from onset to inclusion and, most of all, number of MRI lesions. Tintoré et al. [34] recently produced some useful information when studying 320 patients with CIS followed prospectively for a median of 39 months in an MS clinic in Barcelona, Spain. Inclusion criteria were somewhat less restrictive than trials, but excluded patients older than 50 and those seen more than 3 months after onset. CIS presentation was divided into optic neuritis, brainstem syndrome, myelitis, or other topography. Symptoms had to be suggestive of centralnervous-system demyelination not attribuable to another disease. MS was diagnosed either clinically, when there was a second attack with new neurological abnormalities confirmed by examination, or by MRI MacDonald criteria for dissemination in time and space on two scans acquired a year apart. Among the 320 patients, 72% were women, with a mean age at onset of 29.7 years. Isolated optic neuritis was overrepresented (38.4% of the patients) as compared to natural history series. The other presentations were brainstem syndrome in 24.4%, myelitis in 27.8% and other in 9.4%. Conversion to clinically definite MS was observed in 34.7% of the patients after a median of 14 months. It was not different according to gender and age at onset. It shows, however, that patients with optic neuritis have a smaller risk for converting to MS than patients with other CIS topographies. The authors also demonstrated that this observation was confounded by the results of MRI, and probably also of cerebrospinal fluid analysis. In fact, patients with optic neuritis had significantly fewer abnormal baseline MRIs (51 compared with 75-80%, respectively) and less often had cerebrospinal-fluid IgG oligoclonal bands (40 and 67-79%, respectively) than the others. When selecting only patients with abnormal MRI scans, prognosis was the same among all topographies. This is consistent with the well known fact that optic neuritis with normal MRI and cerebrospinal fluid analysis never converts to MS in a substantial proportion of cases [35] . This induced a bias towards a better prognosis of optic neuritis compared with other CIS topographies. The clue in the diagnosis and the occurrence of a second neurological episode seems then to be the normality of MRI rather than the clinical features.
Conclusion
The general evolution and prognosis of MS is well established in large natural-history series. Recent descriptions emphasize the fact that clinical phenotypes may be mainly age-related, and minimize the role of relapses in the long-term accumulation of disability. However, beyond this apparent global homogeneity in the clinical course, there is still a place for a very wide inter-individual heterogeneity, which is the reason why the individual profile remains largely unpredictable.
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